Detalles de la búsqueda
1.
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer.
Breast Cancer Res
; 26(1): 20, 2024 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-38297352
2.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Lancet Oncol
; 24(3): 273-285, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36858723
3.
Nodal Positivity in Early-Stage Triple-Negative Breast Cancer: Implications for Preoperative Immunotherapy.
Ann Surg Oncol
; 30(1): 100-106, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35941343
4.
CDK4/6 inhibition triggers anti-tumour immunity.
Nature
; 548(7668): 471-475, 2017 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-28813415
5.
Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer.
Nature
; 529(7586): 413-417, 2016 Jan 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-26735014
6.
A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.
Breast Cancer Res Treat
; 189(2): 411-423, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34302589
7.
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer.
Breast Cancer Res Treat
; 187(1): 155-165, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33591468
8.
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial).
Breast Cancer Res Treat
; 189(1): 103-110, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34120223
9.
Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases.
Breast Cancer Res
; 22(1): 131, 2020 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33256829
10.
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Breast Cancer Res
; 22(1): 120, 2020 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33138866
11.
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.
Lancet Oncol
; 20(6): 816-826, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31047803
12.
A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
Breast Cancer Res Treat
; 178(1): 121-133, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31368034
13.
Safety and pharmacokinetics of MM-302, a HER2-targeted antibody-liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study.
Br J Cancer
; 119(9): 1086-1093, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30361524
14.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
N Engl J Med
; 372(2): 134-41, 2015 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-25564897
15.
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.
Breast Cancer Res Treat
; 167(3): 731-740, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29110152
16.
Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.
Proc Natl Acad Sci U S A
; 112(46): 14325-30, 2015 Nov 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-26578779
17.
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 18(6): 732-742, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28526536
18.
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial.
Lancet Oncol
; 18(6): 743-754, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28526538
19.
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 17(6): 811-821, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27155741
20.
Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer.
Breast Cancer Res
; 18(1): 34, 2016 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26979312